Jim Cramer: This Healthcare Stock Is 'Too Risky,' But Shares Jumped 64% Over Past Month
Portfolio Pulse from Avi Kapoor
Jim Cramer, on CNBC's 'Mad Money Lightning Round,' labeled Praxis Precision Medicines (PRAX) as 'too risky' despite its 64% stock jump over the past month following a public offering. He also rejected U.S. Silica Holdings (SLCA) after its Q3 results fell short of expectations. Conversely, Cramer endorsed Tetra Tech (TTEK) following Keybanc's Overweight rating and $191 price target. RxSight (RXST) was noted for losing money, with Cramer seeking further analysis despite Needham's Buy rating and increased price target from $35 to $41.
January 25, 2024 | 1:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tetra Tech received a positive endorsement from Jim Cramer and an Overweight rating with a $191 price target from Keybanc analyst Sangita Jain.
Cramer's endorsement and Keybanc's positive analyst rating with a high price target could attract investor interest, potentially driving up Tetra Tech's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 80
NEUTRAL IMPACT
RxSight is losing money, prompting Jim Cramer to reserve judgment despite Needham's Buy rating and raised price target.
While Needham's positive rating and increased price target could be seen as bullish, Cramer's hesitancy due to the company's losses could create mixed signals for investors, leading to a neutral short-term impact.
CONFIDENCE 70
IMPORTANCE 65
RELEVANCE 60
NEGATIVE IMPACT
Jim Cramer called Praxis Precision Medicines 'too risky' even after a 64% rise in stock price following a public offering.
Cramer's negative sentiment, especially on a high-profile platform like 'Mad Money,' could influence investor perception negatively, potentially impacting the stock's short-term performance.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
U.S. Silica Holdings reported weaker-than-expected Q3 results, leading Jim Cramer to reject the stock.
Poor quarterly results can dampen investor sentiment, and a negative outlook from a prominent market commentator like Cramer could exacerbate the stock's short-term decline.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 70